7 Best Peptides for Macular Degeneration

What to Know Before Choosing a Peptide for Macular Degeneration

The peptide landscape for macular degeneration is genuinely unusual. On one end, you have FDA-approved compounds and peptides currently in Phase I and Phase II human trials, making AMD one of the few conditions where peptide research has reached real clinical validation. On the other end, you have compounds used in Russian and Eastern European medicine for decades, plus a handful of research chemicals that appear in community discussions with little or no formal evidence behind them. This guide covers the whole field.

A peptide earned a slot here because people use it or are actively discussing using it for macular degeneration. FDA approval is not the test, and neither is the depth of the clinical literature. A compound used off-label under physician supervision belongs on this list. A compound that exists primarily as a research chemical and appears mainly in community protocols belongs too, with its evidence described honestly. FDA-approved, telemedicine-accessible, and research-only compounds are all included.

The entries are numbered by how prominently each compound appears in research and documented real-world use, not as a ranking of one being better than another for any individual. Number one is not the best choice for you; it is the compound with the deepest presence in the field at this moment. The right choice depends on your specific situation, the stage and type of AMD involved, what a qualified clinician recommends, and the personalized plan you build with the app.

1. Elamipretide (SS-31): The Furthest Along in Human Trials

Elamipretide, also called SS-31 or MTP-131, is a synthetic tetrapeptide designed specifically to target mitochondria, the energy-producing structures inside cells, and it has the most advanced human clinical record of any peptide being studied specifically for AMD.

The rationale behind it starts with a well-established feature of dry AMD: the retinal pigment epithelium cells that support photoreceptors are under sustained oxidative stress, and their mitochondria progressively deteriorate. Elamipretide works by binding to cardiolipin, a structural fat molecule embedded in the inner mitochondrial membrane that functions as scaffolding for the membrane's energy-producing machinery. When cardiolipin is damaged, the mitochondrial architecture destabilizes, energy production drops, and cells begin dying. Elamipretide stabilizes that membrane, helps restore the electron transport chain, and reduces the reactive oxygen species that drive ongoing damage. Think of the inner mitochondrial membrane as a tightly folded assembly line; cardiolipin is the frame holding the line together, and Elamipretide keeps that frame intact under stress.

Two Phase II clinical trials have been completed for AMD, with trial identifiers NCT03891875 and NCT02693119. Published findings indicate improvement in photopic visual function, which refers to vision under normal daylight conditions, and evidence of mitochondrial preservation in retinal pigment epithelium cells. Elamipretide is also FDA-approved for Barth syndrome, a rare genetic disease involving severe mitochondrial dysfunction, which means some clinicians have prescribed it off-label for AMD based on that existing approval. Access outside clinical trials currently comes through either off-label prescription or research chemical vendors, the latter being unregulated and not something to pursue without substantial caution.

2. Risuteganib: For Blocking the Upstream Angiogenic Cascade

Risuteganib, also known as ALG-1001 or Luminate, takes a different angle than most compounds in this field. While standard-of-care drugs for wet AMD block VEGF, the protein most directly responsible for pathological blood vessel growth, risuteganib works upstream of VEGF by targeting integrin receptors. Integrins are proteins on cell surfaces that act like molecular docking stations, and several of them sit near the start of the signaling chain that drives both inflammation and abnormal vessel growth in wet AMD.

By engaging these integrin receptors earlier in the cascade, risuteganib aims to reduce leukocyte adhesion, lower complement receptor expression, and decrease TNF-alpha pathway activity simultaneously. The clinical rationale is that many patients develop partial resistance to anti-VEGF therapy over time because the disease has multiple drivers upstream of VEGF, and an integrin inhibitor working earlier in that chain might address what anti-VEGF alone misses.

Phase I for AMD was completed with no serious adverse events. In a separate Phase I proof-of-concept study in diabetic macular edema, a related condition involving fluid accumulation in the macula, 8 of 15 participants showed reduced central macular thickness ranging from 30 to 80 percent, with visual acuity improvements of 3 to 5 lines that persisted through a 90-day washout period. A Phase 1b and 2a trial for wet AMD was actively enrolling as of mid-2026. Risuteganib is delivered via intravitreal injection, the same route used by anti-VEGF drugs. Access is currently limited to clinical trial participation.

3. Forzinity (SPIAM-301): The Newest FDA-Approved Entry

Forzinity, the brand name for SPIAM-301, received accelerated FDA approval in September 2025 for intermediate wet and dry AMD as well as geographic atrophy, making it the most recently approved peptide in this space and the only one approved for both forms of the disease simultaneously. It is a mitochondrial peptide, similar in therapeutic rationale to Elamipretide, targeting energy metabolism and oxidative stress in the retinal pigment epithelium.

Accelerated approval means the FDA granted approval based on a surrogate endpoint considered likely to predict clinical benefit, rather than waiting for full long-term outcome data. The Phase 2 trial for Forzinity missed its primary endpoint, which is worth stating plainly, and the Phase 3 ReNEW trial was actively enrolling as of mid-2026. The clinical picture is an approved but still-being-validated therapy: real regulatory endorsement, with ongoing confirmation of benefit still in progress.

Forzinity is administered as a once-daily subcutaneous injection. Access requires a retina specialist prescription, and telemedicine may facilitate the consultation but not the dispensing of the injectable itself. For patients with geographic atrophy or intermediate AMD who want a compound with FDA backing and a mechanistic rationale grounded in published science, Forzinity represents the current frontier of the approved field.

4. 6R-FBP: The Fas-Blocking Approach to Dry AMD

6R-FBP stands for Fas-blocking peptide, and its mechanism targets a specific cell-death pathway called Fas-mediated apoptosis, one of the primary ways photoreceptors and retinal pigment epithelium cells die in dry AMD. Apoptosis is programmed cell death, and the Fas receptor acts like a self-destruct switch on cell surfaces. When the Fas ligand binds that receptor, it triggers a cascade of signaling through caspases, the molecular scissors that execute the death sequence, along with activation of NF-kB and ERK pathways that amplify inflammation.

6R-FBP works by physically blocking the Fas ligand from reaching its receptor, preventing the cascade from initiating. It also promotes internalization of unengaged Fas receptors, reducing the number of available switches on the cell surface. In rodent and rabbit models of retinal degeneration, 6R-FBP administered as eye drops reached the retina and reduced photoreceptor and RPE cell loss. At concentrations up to 900 micromolar in retinal cell experiments, it showed no cytotoxicity, suggesting a reasonable safety profile at the tissue level.

No human clinical trials have been published for 6R-FBP as of 2026. The evidence base is entirely preclinical, meaning it comes from animal models only. It belongs in this field because the Fas apoptosis pathway is well-validated as a driver of photoreceptor loss in dry AMD, and the eye-drop delivery route is a genuine practical advantage over injectable alternatives. Researchers and community members following the AMD pipeline discuss it as one of the more mechanistically credible compounds that has not yet made the transition to human trials.

5. Visoluten: The Russian Peptide Bioregulator for Retinal Support

Visoluten is a peptide bioregulator, sometimes classified as a cytamine, developed in Russia and formulated specifically to support retinal tissue. It is derived from animal retinal extracts and belongs to a class of compounds developed primarily by Russian researcher Professor Vladimir Khavinson. The theoretical framework behind peptide bioregulators holds that short peptides derived from specific tissues act as gene expression modulators, upregulating protective proteins and downregulating degenerative processes in the corresponding target tissue. For Visoluten, that target is the retina.

No published peer-reviewed human clinical trial data exists specifically for Visoluten in macular degeneration. The research base for this class of peptide bioregulators exists largely in Russian-language literature and has not been reproduced in large-scale Western clinical trials. Visoluten is used in Russia and Eastern Europe, and community discussions reference it alongside a related compound called Retinalamin as part of a Russian approach to retinal support. In AMD communities online, Retinalamin has been described as effectively used in Russia for many years for macular degeneration, reflecting genuine use even in the absence of Western trial validation.

Visoluten is available for purchase from international vendors and is not FDA-approved for any indication. The evidence here is experiential and traditional rather than clinical. People who use it are working from the peptide bioregulator framework and from decades of practice in Russian medicine, not from randomized controlled trial data. That is an honest description of where it stands, and it earns a place in this guide because real people are actively using and discussing it for AMD.

6. BPC-157: The Community-Discussed Compound for Retinal Ischemia

BPC-157 is a synthetic 15-amino-acid peptide originally derived from a protein found in gastric juice. It is among the most widely discussed compounds in peptide and biohacking communities, known primarily for tissue healing, anti-inflammatory effects, and gut repair. Its appearance in the AMD conversation is more recent and narrower: a subset of community members discuss using it as self-prepared eye drops mixed in sterile saline, with the proposed mechanism being its anti-ischemic properties. Ischemia refers to reduced blood and oxygen supply to a tissue, and retinal ischemia is part of the pathological picture in certain forms of early AMD.

BPC-157 has been studied in animal models for its ability to promote angiogenesis, meaning new blood vessel formation, upregulate growth factor receptors, and modulate nitric oxide systems involved in vascular tone. The theoretical bridge to retinal use is that these same properties could support blood flow and tissue integrity in early AMD where ischemia is a contributing driver. Community posts describe users claiming reversal of early-onset macular degeneration with self-prepared BPC-157 eye drops, though no controlled data supports, quantifies, or replicates these reports.

No human clinical trial data has been published for BPC-157 in macular degeneration or any other ocular condition as of 2026. The evidence is entirely anecdotal, drawn from a small number of community forum accounts. The preparation method being discussed, dissolving research-grade powder in saline at home for direct ocular use, carries real infection risk from sterility failures and undefined risk of ocular damage from impure compounds. BPC-157 is not FDA-approved for any human use indication and is sold as a research chemical. It belongs in this guide because people are actively discussing and attempting it for AMD, and the honest framing of that reality is more useful to the reader than omitting it.

7. Ac-RLYE: The Phase I Tetrapeptide Showing Early Human Promise

Ac-RLYE is a synthetic tetrapeptide, built from four amino acids, currently in Phase I human trials in South Korea. It is the compound in this guide that combines the most encouraging early human data with the least current availability, because the only access as of mid-2026 is through the ongoing trial itself.

Early Phase I findings stand out: a single dose produced improved visual acuity and reduced macular thickness that persisted for more than 12 weeks. Safety was confirmed in the trial population. In animal studies, Ac-RLYE outperformed ranibizumab, one of the standard anti-VEGF drugs currently used for wet AMD, which sets a high comparison bar and explains the attention it has drawn outside the trial site. The full mechanism has not been detailed in published literature, but the clinical profile suggests anti-angiogenic or neuroprotective action, or a combination of both.

Community interest in Ac-RLYE has grown specifically because of the animal comparison data and the durable single-dose human findings. Its appearance in AMD forums and peptide research discussions reflects genuine interest in whether the South Korean Phase I results will hold through larger trials. It is not available for self-directed use, and given that it is in active clinical trials, that is the appropriate channel for it right now.

How These Peptides Compare

Frequently Asked Questions

Are any peptides for macular degeneration FDA-approved?

Yes, two peptide-related compounds hold FDA approval relevant to AMD. Forzinity (SPIAM-301) received accelerated approval in September 2025 for intermediate wet and dry AMD as well as geographic atrophy and is administered as a subcutaneous injection requiring a retina specialist prescription. Elamipretide is FDA-approved for Barth syndrome and is sometimes prescribed off-label for AMD by retina specialists, though AMD is not its labeled indication. Neither is available over the counter.

Can peptides for AMD be used as eye drops instead of injections?

Several compounds in the research pipeline are specifically being developed as eye drops, including 6R-FBP and others in preclinical stages, because topical delivery would be a major practical advantage over the intravitreal injections required by current wet AMD treatments. As of 2026, none of these eye-drop peptides have completed human trials and none are approved for AMD. Community discussions about self-prepared BPC-157 eye drops exist, but preparing a research chemical at home for direct ocular use carries real infection risk and undefined risk of ocular damage from impure materials.

How does the evidence for these peptides compare to the anti-VEGF drugs already used for AMD?

The anti-VEGF drugs currently used as standard of care for wet AMD have extensive Phase III trial data, long-term real-world outcome records, and full FDA approvals for their specific indications. The peptides in this guide range from having Phase II human data to having no human data at all. AMD is one of the more active areas of peptide clinical research, but none of the experimental compounds here are equivalent to the approved standard at this point. The honest picture is a pipeline with early and intermediate evidence, one recent accelerated approval, and several more compounds approaching human trials.

Is Visoluten the same as Retinalamin?

They are related but distinct compounds. Both are retinal-tissue-derived peptide bioregulators developed in Russia under the framework associated with Professor Vladimir Khavinson, and both are used in Russian and Eastern European medicine for retinal conditions including AMD. Visoluten is an oral peptide bioregulator marketed as a supplement, while Retinalamin is typically administered by injection in Russian clinical settings. Neither is FDA-approved, and neither has published large-scale peer-reviewed trial data from Western studies. People in AMD communities sometimes reference both interchangeably, but they are different products.

Should someone with AMD stop current treatment to try these peptides?

No. Nothing in this guide is a reason to stop or modify existing macular degeneration treatment. The compounds described here range from FDA-approved therapies requiring specialist oversight to research chemicals with no clinical validation. Any decision about AMD treatment should be made with a qualified retina specialist who knows your full history and the current state of your disease. This guide describes what people use and discuss and what the research shows, not what any individual should do.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for macular degeneration in one place.